Shine signs deal with MURR

By staff writers

June 9, 2021 -- Shine Medical Technologies has signed a multiyear deal with the University of Missouri Research Reactor (MURR) covering the production of the precursor isotope to lutetium-177 (Lu-177), a radioisotope used for therapeutic applications.

Under the contract, ytterbium-176, which is the starting material used to produce Lu-177, will undergo irradiation at the MURR's reactor. Lu-177 is a low-energy beta-particle emitter that directly irradiates cancer cells after being delivered to a cancer site. Since it only travels a short distance, the isotope destroys cells without causing major damage to surrounding tissue.

The company will discuss Lu-177 and the progress it has made in commercializing molybdenum-99 at the upcoming Society for Nuclear Medicine and Molecular Imaging (SNMMI) meeting.

Shine selects Netherlands site for new facility
Medical isotope firm Shine Medical Technologies announced it has selected a location in the northern Netherlands for its new production facility.
Shine merges with nuclear technology firm Phoenix
Nuclear technology company Phoenix has become a wholly owned subsidiary of medical isotope firm Shine Medical Technologies, the companies announced.
Shine breaks ground for new headquarters
Shine Medical Technologies has broken ground in Janesville, WI, on a 54,000-sq-ft facility that will serve as its headquarters and a production facility...
Shine makes 1st commercial sales of Lu-177
Medical isotope firm Shine Medical Technologies made its first commercial sales of its lutetium-177 (Lu-177) therapeutic isotope to multiple customers.
Shine closes $80M funding round
Medical isotope firm Shine Medical Technologies has closed a round of financing that raised $80 million for the company.

Copyright © 2021